Showing results (1-10 of 5) with videos related to

Sort By:
Pageof 1
Dermatologic Therapy|August 16, 2022
Guselkumab as a switching strategy after anti-TNFα, anti-IL17, or anti-IL12/23 therapies in moderate-to-severe psoriasisRicardo Ruiz-Villaverde, Lourdes Rodriguez-Fernandez-Freire, Jose Carlos Armario-Hita, et al.
Dermatologic Therapy|September 17, 2022
Guselkumab dosing interval optimization in adult patients with moderate-to-severe psoriasis switching from ustekinumabRicardo Ruiz-Villaverde, Fiorella Vasquez Chinchay, Lourdes Rodriguez-Fernandez-Freire, et al.
F1000Research|December 27, 2022
Effectiveness, survival and safety of guselkumab attending to basal characteristics in moderate-to-severe psoriatic patients: a cohort studyRicardo Ruiz-Villaverde, Lourdes Rodriguez-Fernandez-Freire, Jose C Armario-Hita, et al.
Life (Basel, Switzerland)|September 23, 2022
Super-Responders in Moderate-Severe Psoriasis under Guselkumab Treatment: Myths, Realities and Future PerspectivesRicardo Ruiz-Villaverde, Fiorella Vasquez-Chinchay, Lourdes Rodriguez-Fernandez-Freire, et al.
Dermatology and Therapy|March 9, 2023
Short-Term Effectiveness, Safety, and Potential Predictors of Response of Secukinumab in Patients with Severe Hidradenitis Suppurativa Refractory to Biologic Therapy: A Multicenter Observational Retrospective StudyPablo Fernandez-Crehuet, Sofía Haselgruber, Alicia Padial-Gomez, et al.
Pageof 1